Iris M Otani1, Amy S Levin2, Aleena Banerji2. 1. Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA. iris.otani@ucsf.edu. 2. Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Abstract
PURPOSE OF REVIEW: The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics. RECENT FINDINGS: Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensitivity reactions are relatively common adverse events. A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent.
PURPOSE OF REVIEW: The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics. RECENT FINDINGS: Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. IL-17 inhibitors are unique in increasing risk for Candida infections. Benign injection site reactions, non-specific rash, cellulitis, and hypersensitivity reactions are relatively common adverse events. A wide variety of cutaneous reactions caused by biologics have been reported, ranging from benign injection site reactions to life-threatening cutaneous reactions necessitating discontinuation of the implicated biologic agent.
Authors: Dan Nordström; Ann Knight; Reijo Luukkainen; Ronald van Vollenhoven; Vappu Rantalaiho; Anna Kajalainen; Johan G Brun; Anne Proven; Lotta Ljung; Hannu Kautiainen; Tom Pettersson Journal: J Rheumatol Date: 2012-08-01 Impact factor: 4.666
Authors: Albert Deisseroth; Chia-Wen Ko; Lei Nie; Jeanne F Zirkelbach; Liang Zhao; Julie Bullock; Nitin Mehrotra; Pedro Del Valle; Haleh Saber; Christopher Sheth; Brenda Gehrke; Robert Justice; Ann Farrell; Richard Pazdur Journal: Clin Cancer Res Date: 2015-01-19 Impact factor: 12.531
Authors: K A Papp; C E M Griffiths; K Gordon; M Lebwohl; P O Szapary; Y Wasfi; D Chan; M-C Hsu; V Ho; P D Ghislain; B Strober; K Reich Journal: Br J Dermatol Date: 2013-04 Impact factor: 9.302